New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 1449-1456

  Mekaj, Ymer H ^a,b   Daci, Fetije T ^b   Mekaj, Agon Y ^a  

^a UNIVERSITY OF PRISHTINA   (Serbia)

^b National Blood Transfusion Center of Kosovo   (Serbia)

Author keywords

Arterial thrombosis; Cyclooxygenase inhibitor; Platelet; Recurrent VTE

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; ARACHIDONIC ACID; DABIGATRAN; DALTEPARIN; IDRAPARINUX; PLACEBO; PROSTAGLANDIN SYNTHASE; RIVAROXABAN;

ACUTE CORONARY SYNDROME; ARTERIAL THROMBOEMBOLISM; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ENZYME ACTIVITY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPOPROTHROMBINEMIA; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; MECHANICAL HEART VALVE; META ANALYSIS (TOPIC); MUSCULOSKELETAL DISEASE; PANCYTOPENIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SKIN DISEASE; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

EID: 84942767210     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S92222     Document Type: Review

References (70)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–593.
2. Goldhaber SZ. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol. 1992;19(2): 246–247.
3. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost. 2009; 7 Suppl 1:258–261.
4. Gómez-Outes A, Suárez-Gea ML, Calvo-Rojas G, et al. Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol. 2012;9(2):83–104.
5. Ferlund P, Stenflo J, Roepstorff P, Thomsen J. Vitamin K and the biosynthesis of prothrombin. V. Gamma-carboxyglutamic acids, the vitamin K-dependent structures in prothrombin. J Biol Chem. 1975;250(15): 6125–6133.
6. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998; 114:445S–469S.
7. Klauser W, Dütsch M. Practical management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskelet Surg. 2013;97(3):189–197.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
9. da Silva RM. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovasc Hematol Agents Med Chem. 2014;12(1): 3–8.
10. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–977.
11. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21(7):1094–1096.
12. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10): 668–698.
13. Undas A, Brummel-Ziedins K, Mann KG. Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thromb Haemost. 2014; 12(11):1176–1187.
14. Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000; 321(7276):1591–1594.
15. Patrono C, Coller B, FitzGerald FA, Hirsh J, Roth G. Platelet-active drugs: the relationship among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):234S–264S.
16. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311(19):1206–1211.
17. Wilthauer J, Wohlgemut J. Uber aspirine (acetylsalicylic acid). Ther Mh (Halbmh). 1899;13:276. German.
18. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e89S–e119S.
19. Sato H, Ishikawa K, Kitabatake A, et al; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447–451.
20. authors listed]. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212):1295–1302.
21. Miser WF. Appropriate aspirin use for primary prevention of cardiovascular disease. Am Fam Physician. 2011;83(12):1380–1386.
22. Tóth L, Muszbek L, Komáromi I. Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. J Mol Graph Model. 2013;40:99–109.
23. Lei J, Zhou Y, Xie D, Zhang Y. Mechanistic insights into a classic wonder drug – aspirin. J Am Chem Soc. 2015;137(1):70–73.
24. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007;115(16): 2196–2207.
25. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood. 1993;82(2):505–512.
26. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366–1372.
27. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012; 32(8):1777–1783.
28. Meier TR, Myers DD Jr, Wrobleski SK, et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost. 2008;99(2):343–351.
29. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which? Where? When? Arterioscler Thromb Vasc Biol. 2009;29(12): 1989–1996.
30. Szczeklik A, Krzanowski M, Góra P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992;80(8): 2006–2011.
31. Brown AE, Litvinov RI, Discher DE, Purohit PK, Weisel JW. Multiscale mechanics of fibrin polymer: gel stretching with protein unfolding and loss of water. Science. 2009;325(5941):741–744.
32. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thomb Vasc Biol. 2011;31(3):494–499.
33. Loew D, Vinazzer H. Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors. Haemostasis. 1976;5(4):239–249.
34. Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation. 2003;107(1):17–20.
35. Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med. 2012;367(21):2039–2041.
36. Yasue H, Ogawa H, Tanaka H, et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol. 1999;83(9):1308–1313.
37. Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014;12(3 4):147–154.
38. Ho LL, Brighton T. Warfarin, antiplatelet drugs and their interactions. Aust Prescr. 2002;25:81–85.
39. Morimoto T, Nakayama M, Saito Y, Ogawa H. Aspirin for primary prevention of atherosclerotic disease in Japan. J Atheroscler Thromb. 2007;14(4):159–166.
40. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.
41. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162(1):115–124.e2.
42. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209–216.
43. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl): e576S–e600S.
44. Vandvik PO, Lincoff AM, Gore JM, et al; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e637S–e668S.
45. You JJ, Singer DE, Howard PA, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–e575S.
46. Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473.
47. Lansberg MG, O’Donnell MJ, Khatri P, et al; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy And Prevention Of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl): e601S–e636S.
48. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977;297(23):1246–1249.
49. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry. Chest. 2003;124(6 Suppl): 349S–356S.
50. Hovens MM, Snoep JD, Tamsma JT, Huisman MW. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost. 2006;4(7):1470–1475.
51. Becattini C, Agnelli G, Schenone A, et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Eng J Med. 2012;366(21):1959–1967.
52. Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979–1987.
53. Čulić V. Aspirin for preventing venous thromboembolism. N Engl J Med. 2013;368(8):772.
54. Paraskevas KI. Aspirin for preventing venous thromboembolism. N Engl J Med. 2013;368(8):772–773.
55. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295(12): 1420–1427.
56. Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med. 2011;124(9): 852–859.
57. Simes J, Becattini C, Agnelli G, et al; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13): 1062–1071.
58. Sobieraj DM, Coleman CI, Pasupuleti V, Deshpande A, Kaw R, Hernandez AV. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thromb Res. 2015;135(5):888–896.
59. Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013; 158(11):800–806.
60. Prandoni P, Noventa F, Milan M. Aspirin and recurrent venous thromboembolism. Phlebology. 2013;28 Suppl 1:99–104.
61. Weitz JI, Bauersachs R, Beyer-Westendorf J, et al; EINSTEIN CHOICE Investigators. Two doses of rivaroxaban versus aspirin for the prevention of recurrent venous thromboembolisms. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost. 2015;114(3): 645–650.
62. Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25(7): 1053–1060.
63. Jiang Y, Du H, Liu J, Zhou Y. Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chin Med J (Engl). 2014;127(12): 2201–2205.
64. Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother. 2013;47(1):63–74.
65. Knesek D, Peterson T, Markel DC. Thromboembolic prophylaxis in total joint arthroplasty. Thrombosis. 2012;2012:837–896.
66. Jameson SS, Baker PN, Deehan DJ, Port A, Reed MR. Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement. Bone Joint Res. 2014;3(5):146–149.
67. Thorat MA, Cuzick J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol. 2015;30(1):5–18.
68. Fausa O. Salicylate-induced hypoprothrombinemia. A report of four cases. Acta Med Scand. 1970;188(5):403–408.
69. Garg SK, Sarker CR. Aspirin-induced thrombocytopenia on an immune basis. Am J Med Sci. 1974;267(2):129–132.
70. Wijnja L, Snijder JA, Nieweg HO. Acetylsalicylic acid as a cause of pancytopenia from bone-marrow damage. Lancet. 1996;2(7467): 768–770.